Shares of Novavax Inc. NVAX slid 3.46% to $9.22 Friday, on what proved to be an all-around rough trading session for the ...

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.55 which represents a slight increase of $0.72 or 8.15% from the prior close of $8.83. The stock opened at $8.82 and touched a low of ...

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

Shares of Novavax Inc. NVAX shed 1.52% to $8.40 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.51% to 19,630. ...

$100,000 of NOVAVAX INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...